Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9282938 | 0.91 | PTPN1 (0.45) | KCNA3PTPN1LMNAHPGDMEN1 | |
| SCHEMBL9282750 | 0.91 | PTPN1 (0.43) | KCNA3PTPN1LMNAHPGDMAOB | |
| SCHEMBL9282847 | 0.90 | KCNA3 (0.41) | KCNA3PTPN1LMNAHPGDMEN1 | |
| SCHEMBL6125213 | 0.87 | PTPN1 (0.40) | KCNA3PTPN1LMNAHPGDMAOB | |
| SCHEMBL20370139 | 0.86 | PTPN1 (0.45) | PTPN1LMNAHPGDMEN1KMT2A | |
| SCHEMBL9284160 | 0.86 | RAB9A (0.41) | KCNA3PTPN1LMNAHPGDKMT2A | |
| SCHEMBL12109480 | 0.85 | LMNA (0.39) | KCNA3PTPN1LMNAHPGDMAOB | |
| SCHEMBL12108837 | 0.84 | PTPN1 (0.38) | KCNA3PTPN1LMNAHPGDMAOB | |
| SCHEMBL18524982 | 0.84 | PTPN1 (0.41) | PTPN1LMNAHPGDMEN1KMT2A | |
| SCHEMBL9282987 | 0.83 | PTPN1 (0.40) | PTPN1LMNAHPGDKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | KCNA3 3725/4885PTPN1 402/4885LMNA 3089/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | KCNA3 3725/4885PTPN1 402/4885LMNA 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.